- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Role of PCSK9 Inhibitors for Patients with Hyperlipidemia
Zachary T. Bloomgarden, MD, MACE: We know that some individuals will receive a potent statin, or as much of a statin as they can tolerate (because some people develop really burdensome musculoskeletal complaints with statins). Yet, we’ll have evidence of atherosclerotic cardiovascular disease and have LDL (low-density lipoprotein) cholesterol levels [that] are above goal.
For such individuals, we now have a few choices [for treatment]. We can use the bile acid binding resins. We can use ezetimibe. We now can use the PCSK9 (proprotein convertase subtilisin kexin 9) inhibitors, which are tremendously potent agents for lowering LDL cholesterol and seem to be rather well tolerated.
I think this, essentially, represents a huge advance in the way that the dyslipidemia will be treated going forward. There’s the cost issue. There’s all these other things which are so important. So, we have to see how it all plays out, but the fact that we have so many choices is only going to help us to do a better job.
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Semaglutide Linked to Cardiovascular Gains, but Also Higher Health Spending
August 8th 2025A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and cholesterol, but also a $80 monthly rise in health care spending outside of drug costs.
Read More
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
August 6th 2025Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Read More
